louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03260985: Precision Psychiatry Continuity Clinic Project
Official title: Precision Psychiatry Continuity Clinic Project
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depressive Disorders
Depressive Symptoms
Anxiety Disorders and Symptoms
Psychological Distress
Mood Disorders
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2017-08-24
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This is a demonstration project focused on translating neuroscience insights into clinical practice. The researchers will evaluate how neuroscience assessments may be applied in the clinical setting to help inform care decisions. The aim of the study is to undertake a pragmatic pilot trial to assess whether the inclusion of structured feedback from neuroscience assessments has an effect on improving patient outcomes. The study will investigate how neuroscience assessments can be integrated into and improve clinical care. The impact of sharing information and conclusions from these assessments with psychiatric providers will be explored. Outcomes will include symptoms, social/occupational function and qualify of life.


Eligibility criteria: Inclusion Criteria:

* 18+ years of age
* Fluent and literate in English, and able to understand task instructions
* fMRI scanning eligibility, including no evidence of any form of metal embedded in the body (e.g., metal wires, nuts, bolts, screws, plates, sutures)
* Must be referred for treatment at the Stanford Department of Psychiatry Continuity Clinic

Exclusion Criteria:

* Presence of suicidal ideations representing imminent risk
* General medical condition, disease or neurological disorder that interferes with the assessments
* Traumatic brain injury (history of physical brain injury or blow to the head resulting in loss of consciousness greater than five minutes) and which could interfere with doing the assessments
* Severe impediment to vision, hearing and/or hand movement, likely to interfere with ability to complete the assessments, or are unable and/or unlikely to follow the study protocols
* Pregnancy
* Presence of acute psychosis, schizophrenia spectrum, or other psychotic disorders
* Concurrent participation in intervention or treatment studies

Primary outcomes:
measure: Patient Health Questionnaire (PHQ-9)
timeFrame: 12 weeks
measure: Generalized Anxiety Disorder Questionnaire (GAD-7)
timeFrame: 12 weeks
Secondary outcomes:
measure: Sheehan Disability Scale (SDS) of Social/Occupational Functioning
timeFrame: 12 weeks
measure: Frequency, Intensity, and Burden of Side Effects Ratings (FIBSER)
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford Center for Cognitive and Neurobiological Imaging (CNI)
state: California
Study officials:
affiliation: Stanford University
name: Leanne Williams, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05516485: Measuring Brain Tumor Consistency Using Magnetic Resonance Elastography
Official title: Measuring Brain Tumor Consistency Using Magnetic Resonance Elastography
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Brain Neoplasm
Lead sponsor: University of Southern California
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2022-08-25
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This clinical trial tests whether a new imaging technique called magnetic resonance elastography (MRE) is useful in determining the consistency of brain tumors and whether this could be used to guide surgical planning and choice of approach (the type of surgery that is needed) for patients with brain tumors. Comparing MRE with the typical magnetic resonance imaging (MRI) scan may help researchers assess the quality, reliability, and diagnostic utility of this scan when evaluating brain tumors.

Detailed description: PRIMARY OBJECTIVES:

I. Examine tolerance interval of MRE measurement in kilopascals (kPa) and associated distribution of percent stiff (hard) and soft tumors above the higher limit and below the lower limit.

II. Through machine learning with MRE and clinical/demographic factors, to identify diagnostic thresholds in separating stiff tumor from soft tumor.

OUTLINE:

Patients undergo MRE scan over 25 minutes before surgery at the time of standard of care pre-operative MRI scan. On the day of surgery, the surgeon grades and records tumor consistency/stiffness during the operation and afterwards.

Eligibility criteria: Inclusion Criteria:

* All patients 18 years of age or older who undergo surgical resection for brain tumor at Keck Medical Center of University of South Carolina (USC) are eligible for inclusion into this study

Exclusion Criteria:

* Patients who cannot tolerate MRE
* Those ineligible for MRI due to metallic implants, claustrophobia, or body habitus too large to fit in our MRI machine
* Those not undergoing surgical resection of brain tumor
* Children under the age of 18, pregnant women, wards of the state, and prisoners
* There will be no exclusion of patients based on gender, racial or ethnic origin

Primary outcomes:
measure: Tumor stiffness (hardness) (based on surgeon's grading)
timeFrame: Baseline to 6 weeks
measure: Tumor stiffness (based on MRE)
timeFrame: Baseline to 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: USC / Norris Comprehensive Cancer Center
state: California
Study officials:
affiliation: University of Southern California
name: Mark S Shiroishi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00621985: Dexamethasone Treatment of Congenital Adrenal Hyperplasia
Official title: Dexamethasone Treatment of Congenital Adrenal Hyperplasia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Adrenal Hyperplasia, Congenital
Lead sponsor: Boston Children's Hospital
Sponsor class: OTHER
First posted: 2008-02-22
Enrollment: 5
Sex: ALL
Minimum age (years): 2
Maximum age (years): 9
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if dexamethasone given at night is a more effective treatment for congenital adrenal hyperplasia in young children than standard three times per day hydrocortisone. Our hypothesis is that nocturnal dexamethasone will lead to more efficient suppression of the hypothalamic-pituitary-adrenal axis. We performed a cross-over trial comparing hormonal control during two 24-hour hospitalizations, one on hydrocortisone and one on nocturnal dexamethasone.

Detailed description: This is a Phase II clinical trial, intended to estimate the effect of instituting Dexamethasone therapy in comparison to prior standard therapy. Each subject provides his own baseline data. There is no control group. Patients with CAH who meet inclusion criteria will be admitted to the clinical research center for two 24 hour hospitalizations. Adrenal hormone profiles will be measured during each hospitalization. The patient will take his or her baseline hydrocortisone regimen during one hospitalization and a new regimen consisting of a single daily nocturnal dose of Dexamethasone during the second hospitalization.

Eligibility criteria: Inclusion Criteria:

* Classic salt-wasting 21-hydroxylase deficient congenital adrenal hyperplasia
* Pre-pubertal children with bone ages below 8 years

Exclusion Criteria:

* Age less than 2 years
* Patients with additional medical conditions necessitating glucocorticoid therapy.
* Patients on phenytoin, barbiturates, and rifampin as these medications accelerate the metabolism of glucocorticoids.
* Patients on ketoconazole as this medication increases the bioavailability of glucocorticoids.

Primary outcomes:
measure: Percent Difference in the Mean Log Transformed Area Under the Curve of 17-hydroxyprogesterone Between Regimens
timeFrame: 23 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Children's Hospital Boston
state: Massachusetts
Study officials:
affiliation: Boston Children's Hospital
name: Joseph Majzoub, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Dauber A, Feldman HA, Majzoub JA. Nocturnal Dexamethasone versus Hydrocortisone for the Treatment of Children with Congenital Adrenal Hyperplasia. Int J Pediatr Endocrinol. 2010;2010:347636. doi: 10.1155/2010/347636. Epub 2010 Sep 14.
Clinical trial NCT03441685: Strategies for Teaching Verbs
Official title: Strategies for Teaching Verbs
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Language Development Disorders
Down Syndrome
Child Language
Lead sponsor: Vanderbilt University Medical Center
Sponsor class: OTHER
First posted: 2018-02-22
Enrollment: 44
Sex: ALL
Minimum age (years): 3
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: All participants complete the three intervention conditions within a single session. Order of conditions is counterbalanced across participants.
Primary purpose: TREATMENT

Brief summary: This study is designed to evaluate whether children with Down syndrome and children with typical development exhibit different levels of accuracy demonstrating novel verbs taught under three conditions: semantic cues (perform action), syntactic cues (sentence frame), and combined (syntactic and semantic cues). The participants complete an eligibility evaluation and then one verb learning session (approximately 60 minutes in length). During that verb learning session they are taught sets of words under each condition (i.e., within-subjects design) and then asked to identify and label those target words immediately after instruction.


Eligibility criteria: Inclusion Criteria:

* Must use oral communication as their primary means of communication
* Must be monolingual English speakers
* Behaviorally able to attend for 20 minutes
* Children with typical development must demonstrate no more than one standard deviation below the mean on the speech and language measures

Exclusion Criteria:

* Nonverbal cognitive score less than three standard deviations below the mean (standard score of 54 below)
* Identified hearing loss or failed hearing screening
* Uncorrected vision impairment
* Motor impairment that prevents completion of study activities
* Concomitant disorders (e.g., Autism spectrum disorder)

Primary outcomes:
measure: Accuracy Identifying Taught Words - Syntactic Condition
timeFrame: From date of initial evaluation to focused intervention session, up to 1 month
measure: Accuracy Identifying Taught Words - Semantic Condition
timeFrame: From date of initial evaluation to focused intervention session, up to 1 month
measure: Accuracy Identifying Taught Words - Combined Condition
timeFrame: From date of initial evaluation to focused intervention session, up to 1 month
Secondary outcomes:
measure: Accuracy Labeling Taught Words - Syntactic Condition
timeFrame: From date of initial evaluation to focused intervention session, up to 1 month
measure: Accuracy Labeling Taught Words - Semantic Condition
timeFrame: From date of initial evaluation to focused intervention session, up to 1 month
measure: Accuracy Labeling Taught Words - Combined Condition
timeFrame: From date of initial evaluation to focused intervention session, up to 1 month
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt Bill Wilkerson Center
state: Tennessee
Study officials:
References:
Clinical trial NCT06936085: Forensic Case and Forensic Evidence Management Training: Paramedic Student Example
Official title: Forensic Case and Forensic Evidence Management Training: Paramedic Student Example
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Training Effectiveness
Training
Student Education
Lead sponsor: Uludag University
Sponsor class: OTHER
First posted: 2025-04-20
Enrollment: 144
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study aimed to provide forensic case and evidence management training to paramedic students and to evaluate the effect of the training on the knowledge level of the students.


Eligibility criteria: Inclusion Criteria:

* Paramedic students studying in the 1st and 2nd grades of the First and Emergency Aid Programme who volunteered to participate in the study.

Exclusion Criteria:

* Paramedic students who are not studying in the First and Emergency Aid Programme and who did not volunteer for the research

Primary outcomes:
measure: questionnaire
timeFrame: The evaluation was performed on the same day before and after the training.
Secondary outcomes:
Other outcomes:
Locations:
city: Bursa
country: Turkey
facility: Bursa Uludag University
state: Nilüfer
Study officials:
References:
Clinical trial NCT00282685: Safety and Feasibility Study of Autologous Progenitor Cell Transplantation in Diabetic Neuropathy
Official title: (Restoration of Nerve Functions by Intra-arterial Transplantation of Bone Marrow Progenitor Cells in Patients With Diabetic Poly Neuropathy (PNP)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Diabetic Neuropathies
Keywords: Patients with symmetric peripheral diabetic neuropathy
Lead sponsor: Johann Wolfgang Goethe University Hospital
Sponsor class: OTHER
First posted: 2006-01-27
Enrollment: 7
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Treatment of patients with diabetic neuropathy by intraarterial progenitor cell transplantation.

Detailed description: Goal is:

Stimulation of angiogenesis and induction of vasa nervorum in order to improve nerve function

Eligibility criteria: Inclusion Criteria:

* Patients with distal symmetrical diabetic neuropathy of the legs
* Type 1 or Type 2 Diabetes
* Stable Glucose control over last 3 months (Hba1c \<7.5)
* Written informed consent

Exclusion Criteria:

* Patients with peripheral arterial disease (ABI \<0.9)
* Neuropathy of other origin
* Myopathy
* Asymmetrical neuropathy
* Active infection oder fever
* Chronic inflammatory disease (z.B M. Crohn, Rheumatoid Arthritis)
* HIV or hepatitis
* Neoplastic disease without complete remission within last 5 y
* Stroke or myocardial infarction within last 3 months
* Renal failure (creatinine \> 2 mg/dl)
* Liver disease (GOT \> 2 upper limit or spontaneous INR \> 1,5).
* Anemia (hemoglobine \< 8.5 mg/dl)
* Platelets \<100.000/µl
* HbA1c \>7,5 %
* Allergies to Aspirin, Clopidogrel, Heparin
* Bleeding disorder
* Surgery or trauma within the last 2 months
* Pregnancy
* Mental retardation
* Participation in another study within 30 days

Primary outcomes:
measure: Improvement of neurological score: modified NIS(LL)+7
timeFrame: 1 year
Secondary outcomes:
measure: Modified Toronto Clinical Scoring System
timeFrame: 1 year
measure: Heart rate variability
timeFrame: 1 year
Other outcomes:
Locations:
city: Frankfurt
country: Germany
facility: Div. of Cardiology and Vascular Medicine
Study officials:
affiliation: Div. of Cardiology, University of Frankfurt, Germany
name: Andreas M Zeiher, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Div. of Cardiology, University of Frankfurt, Germany
name: Dirk H Walter, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02148185: Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease
Official title: A Phase I, Open-label Study to Evaluate PK, PD, and Safety of a Single Oral Dose of MT-1303 in Subjects With Moderate to Severe Crohn's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Crohn's Disease
Keywords: Crohn's disease
Lead sponsor: Mitsubishi Tanabe Pharma Corporation
Sponsor class: INDUSTRY
First posted: 2014-05-28
Enrollment: 1
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate PK, PD and safety of a single oral dose of MT-1303 in subjects with Crohn's disease.

Detailed description: This is a Phase I, open-label, non-randomised, multicenter single-dose study to evaluate PK, PD, and safety of a single oral dose of MT-1303 in subjects with moderate to severe active Crohn's disease (ileal and ileo-colonic type).

Eligibility criteria: Inclusion Criteria:

* Subjects who were diagnosed as Crohn's disease
* Subjects who were confirmed as ileal or ileo-colonic type by image inspection.
* Disease severity determined as either "moderate" or "severe"

Exclusion Criteria:

* Present or past history of gastrointestinal surgery which may have impact on drug absorption
* Subjects with stenosis or fistula in small intestine or colon

Primary outcomes:
measure: Plasma concentration of MT-1303
timeFrame: 15 time points up to 29 days
measure: Plasma concentration of MT-1303 metabolite
timeFrame: 15 time points up to 29 days
Secondary outcomes:
measure: Change from baseline in lymphocyte count after MT-1303 administration
timeFrame: 16 time points up to 29 days
measure: Type of adverse events
timeFrame: 29 days
Other outcomes:
Locations:
city: Chubu
country: Japan
facility: Inverstigational site
city: Kanto
country: Japan
facility: Inverstigational site
Study officials:
affiliation: Tokyo Medical and Dental University
name: Mamoru Watanabe, MD
role: STUDY_DIRECTOR
affiliation: Mitsubishi Tanabe Pharma Corporation
name: Kazuoki Kondo, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03823885: ECigs, Inflammation and Oxidative Stress
Official title: E-Cigarettes and Monocytes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: E-cigarettes, Oxidative Stress, Inflammation
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
Collaborators: name: Tobacco Related Disease Research Program
First posted: 2019-01-31
Enrollment: 148
Sex: ALL
Minimum age (years): 21
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Crossover with 2 week washout
Primary purpose: BASIC_SCIENCE

Brief summary: Randomized controlled trial of acute use of electronic cigarette effect on oxidative stress and inflammation.

Detailed description: Participants will have an acute e-cig exposure on 2 occasions 1) e-cigarette 2) sham e-cig (empty e-cig) control. Blood will be collected before and after E-cig use and analyzed for biomarkers of inflammation and oxidative stress.

Eligibility criteria: Inclusion Criteria:

* Healthy

Exclusion Criteria:

* Cardiac disease Respiratory disease Diabetes

Primary outcomes:
measure: Cellular Reactive Oxygen Species, units = % fluorescence
timeFrame: within 4 hours of E-cig use
Secondary outcomes:
measure: CD 14+ Monocyte, units = % of total cells
timeFrame: within 4 hours of e-cig use
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: UCLA
state: California
Study officials:
References:
citation: Kelesidis T, Tran E, Arastoo S, Lakhani K, Heymans R, Gornbein J, Middlekauff HR. Elevated Cellular Oxidative Stress in Circulating Immune Cells in Otherwise Healthy Young People Who Use Electronic Cigarettes in a Cross-Sectional Single-Center Study: Implications for Future Cardiovascular Risk. J Am Heart Assoc. 2020 Sep 15;9(18):e016983. doi: 10.1161/JAHA.120.016983. Epub 2020 Sep 8.
Clinical trial NCT03039985: All-ceramic Crowns in Patients With Sleep Bruxism
Official title: All-ceramic Crowns in Patients With Sleep Bruxism - a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sleep Bruxism
Monolithic Ceramic Fixed Dental Prosthesis (Single Crowns)
Lead sponsor: Heidelberg University
Sponsor class: OTHER
Collaborators: name: German Research Foundation
First posted: 2017-02-01
Enrollment: 109
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the study is to evaluate the complication rate of 2 types of all-ceramic crowns in patients with or without bruxism.


Eligibility criteria: Inclusion Criteria:

* need a molar crown
* tooth antagonist (no implant)

Exclusion Criteria:

* no Antagonist pregnancy, bleeding, periodontal diseases

Primary outcomes:
measure: Success of all-ceramic crowns as determined by complication rate
timeFrame: up to 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Heidelberg
country: Germany
facility: Department of Prosthodontics, University of Heidelberg
Study officials:
affiliation: Heidelberg University
name: Brigitte Ohlmann, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Würzburg
name: Marc Schmitter, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ohlmann B, Rathmann F, Bomicke W, Behnisch R, Rammelsberg P, Schmitter M. Validity of patient self-reports and clinical signs in the assessment of sleep bruxism based on home-recorded electromyographic/electrocardiographic data. J Oral Rehabil. 2022 Jul;49(7):720-728. doi: 10.1111/joor.13327. Epub 2022 Apr 11.
citation: Ohlmann B, Bomicke W, Behnisch R, Rammelsberg P, Schmitter M. Variability of sleep bruxism-findings from consecutive nights of monitoring. Clin Oral Investig. 2022 Apr;26(4):3459-3466. doi: 10.1007/s00784-021-04314-8. Epub 2021 Dec 3.
citation: Ohlmann B, Bomicke W, Habibi Y, Rammelsberg P, Schmitter M. Are there associations between sleep bruxism, chronic stress, and sleep quality? J Dent. 2018 Jul;74:101-106. doi: 10.1016/j.jdent.2018.05.007. Epub 2018 May 17.
Clinical trial NCT00192985: Does a Nitrofurazone Coated Bladder Catheter Reduce the Number of Urinary Tract Infections in Trauma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Trauma
Urinary Tract Infections
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2005-09-19
Enrollment: 216
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Urinary tract infections occurs in trauma. We investigate whether a nitrofurazone coated can reduce the number of urinary tract infections.

Detailed description: Urinary tract infection occurs in one in five patients as a complication following severe trauma. A new and approved urinary bladder catheter (Releen NF) has been introduced by the Danish company Coloplast A/S. Releen NF is expected to reduce the number of urinary tract infections, but this effect has not been investigated in trauma patients.

Eligibility criteria: Inclusion Criteria:

* Clinical suspicion of multiple trauma
* Age \>/= 18 years
* Direct referral from scene of accident
* Indication for urinary bladder catherization

Exclusion Criteria:

* Major burn injury
* HIV positiv
* Pregnancy

Primary outcomes:
measure: urinary tract infections
Secondary outcomes:
measure: length of stay
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Rigshospitalet, Copenhagen University Hospital
Study officials:
affiliation: Rigshospitalet, Denmark
name: Jakob Stensballe, MD
role: STUDY_CHAIR
References:
citation: Stensballe J, Tvede M, Looms D, Lippert FK, Dahl B, Tonnesen E, Rasmussen LS. Infection risk with nitrofurazone-impregnated urinary catheters in trauma patients: a randomized trial. Ann Intern Med. 2007 Sep 4;147(5):285-93. doi: 10.7326/0003-4819-147-5-200709040-00002.